I
ntegration of retroviral DNA into the host cell genome is required for virus replication and is mediated by viral integrase (IN) (Fig. 1) . IN first removes two nucleotides from the 3Ј end of each strand of the nascent viral DNA, leaving a recessed 3Ј CA dinucleotide (3Ј processing). After migration into the nucleus of the infected cell as part of a nucleoprotein complex, IN covalently attaches each 3Ј processed viral end to the host cell DNA (strand transfer). Both 3Ј processing and strand transfer are divalent cation-requiring trans-esterification reactions catalyzed at a single active site in the enzyme's core (1) .
Sequence alignments (2, 3) , mutagenesis (4) (5) (6) (7) (8) (9) , and proteolytic digestion (5) suggest a three-domain structure for HIV-1 IN. The N-terminal domain, residues 1-51, contains a conserved ''HH-CC'' motif that binds zinc in a 1:1 stoichiometry (10). The central catalytic core domain, residues 52-210, contains the catalytic site characterized by three invariant essential acidic residues, D64, D116, and E152. The C-terminal domain, amino acids 220-288, contributes to DNA binding and oligomerization necessary for the integration process (11) and is linked to the catalytic core by residues 195-220, an extension of the final helix of the core domain.
Prior efforts to crystallize full-length HIV-1 IN have been hampered by poor solubility. The mutation F185K markedly improved solubility of the central IN catalytic core domain to over 25 mg͞ml and led to its crystal structure (12, 13) . Structures of the individual N-terminal (14, 15) and C-terminal domains (16) (17) (18) have been determined by NMR. Like the catalytic core domain, each isolated terminal domain dimerizes in solution. Multidomain structures would provide insight into the relative spatial arrangement of the three domains, how IN binds to the host DNA and the viral DNA ends (att sites) during the 3Ј processing and strand transfer reactions, and the oligomeric state of the active enzyme. To address these questions, we sought first to develop a more soluble form of functional, full-length IN (IN 1-288 ) for crystallization.
The introduction of five point mutations, C56S, W131D, F139D, F185K, and C280S, improved the solubility of full-length IN and allowed for its crystallization. To date, however, IN crystals have diffracted to 8-Å resolution. Truncations of the penta-mutated IN 1-288 yielded a 2.8-Å resolution crystal structure of a two-domain construct involving the catalytic core and the C-terminal domains ) and a 1.6-Å resolution crystal structure of the catalytic core domain (IN 52-210 ) as reported here.
Materials and Methods
Mutagenesis. Mutations C56S, W131D, F139D, F185K, and C280S were introduced into a synthetic full-length HIV-1 IN (SF1) sequence in a pT7-7 vector by using oligonucleotide mutagenesis. An N-terminal 6-histidine (6-His) tag followed by a thrombin cleavage site (Stratagene) was added to facilitate purification. One-and two-domain truncation constructs, IN 52-210 and IN 52-288 , were generated from the penta-mutated IN . All mutations, the 6-His tag, and the thrombin cleavage site were confirmed by DNA sequencing.
IN Expression and Purification. The 6-His-tagged IN 52-288 was expressed in BL21 cells by using the pT7-7 isopropyl ␤-Dthiogalactoside-inducible promoter. After sonication and dounce lysis, the protein was purified by using a Ni 2ϩ column (Qiagen, Chatsworth, CA). After thrombin (Novagen) cleavage, thrombin was removed by passage over a benzamidine column (Amersham Pharmacia). The cleaved 6-His tag and any uncleaved protein were removed by passage over a Ni 2ϩ column. Purified IN 52-288 migrated as a single band on SDS͞PAGE. Identical methods were used to purify IN 52-210 . Purified protein was filtered (0.8͞0.2 m syringe filter; Gelman), concentrated by high-pressure, stirred-cell ultrafiltration (YM-10 membrane; Amicon), and dialyzed against 10 mM Hepes (pH 7.0), 500 mM NaCl, and 3 mM DTT. The final protein concentration ranged from 8 to 12 mg͞ml or 6 to 10 mg͞ml as determined by Bradford assay using a BSA standard or absorption at 280 nm with a calculated extinction coefficient of 37 (19) . The structure of the core alone, IN 52-210 , was solved by molecular replacement applied in CNS (20) by using the IN (F185K) catalytic core (21) as a search model (Protein Data Bank code 1bis). The rotation function yielded a clear solution, which gave an unambiguous translation solution. Difference Fourier refinement (22) and manual rebuilding using CHAIN (23) were interspersed with positional, B factor, and simulated annealing protocols in CNS to define the structure.
The structure of two-domain IN 52-288 was solved first by location of the catalytic core dimer by molecular replacement, as implemented in CNS with the 1. (17) into the density maps using EPMR (24) . These domains were located with correlation coefficients of 0.41 (next highest 0.39), and 0.44 (next highest 0.41). The solution clarified the helical linkages between the catalytic core and C-terminal domains. The initial R cryst for the catalytic core domain dimer plus the two C-terminal domains, the dimeric IN 52-288 structure, was 48.7%.
The IN 52-288 structure was refined by using rigid body, positional, B factor, and simulated annealing protocols in CNS. Parallel refinements run with and without NCS restraints gave lower R cryst and R free values without restraints, suggesting that the two monomers had different microstructures determined by their different environments. NCS restraints were therefore not applied.
Results
Mutagenesis to Increase IN Solubility. In addition to the previously described F185K mutation (12, 13), we introduced mutations W131D and F139D to eliminate two hydrophobic residues on the core surface (12) and mutations C56S and C280S to minimize oxidation (25 , grew in a previously uncharacterized crystal form (space group P3 2 , a ϭ 48.9, c ϭ 103.6 Å, one dimer͞asymmetric unit) and diffracted beyond 1.6-Å resolution. This structure was solved by molecular replacement and refined to a R cryst of 25.2%, R free of 26.9% for all reflections to 1.6 Å ( Table 1) . The structure has the same ␣-␤ fold and dimer interface as seen in previous structures of the catalytic core domain of HIV-1 IN (12, 13, 21, 26, 27) , simian immunodeficiency virus (SIV) IN (28), and Rous sarcoma virus (RSV) IN (29) . The mutations introduced to improve IN solubility therefore did not change the catalytic core domain crystal structure. Table 1 ). The catalytic core domain within IN 52-288 forms a symmetric dimer that is very similar to the crystal structure of the isolated catalytic core domain, IN 52-210 (C␣ rms deviation of 0.6 Å between monomers) (30) . Each catalytic core domain of the IN 52-288 dimer is linked to the C-terminal domain by residues 195-220 of helix ␣6. The divergent orientation of the two linking ␣6 helices within the dimer places the centers of the C-terminal domains Ϸ55 Å apart within the dimer, imparting a ''Y'' shape to the IN 52-288 structure ( Fig. 2 a and b) . However, the orientations of the two C-terminal domains differ by Ϸ90°with respect to their 2-fold-related positions, gauged by using the 2-fold axis of the catalytic core domain (Fig. 2 ). An electrostatic potential map identifies a contiguous strip of positive charge along the outer face of the IN 52-288 dimer, beginning at the active site of one monomer and extending along the linking ␣6 helix of the other monomer (Fig. 3a) .
All residues from position 56-137, 150-185, and 195-212 of the catalytic core domain within IN 52-288 were clearly defined in conformation in both monomers. Residues 138-149 in the active site region, and residues 186-194 between the ␣5 and ␣6 helices, are flexible loops in poorly defined density, as previously noted in other unliganded core domain structures (12, 26, 31) . However, residues 138-141 and 145-149 could be interpreted in monomer A, and the 186-194 loop in both monomers could be built into weak density based on its location in the 1.6-Å resolution IN 52-210 structure. Residues 210-270 containing linking helix ␣6 and the C-terminal domain were ordered in both monomers of the IN 52-288 dimer. Residues 271-288 are not clearly defined in density maps.
The average B factor of the catalytic core domain atoms within IN 52-288 is 85 Å 2 , much higher than the 33 Å 2 seen in the 1.6-Å IN 52-210 structure of the isolated catalytic core domain. In contrast, the C-terminal domains of IN , which form nearly all of the dimer-dimer crystal contacts, have an average B factor of 47 Å 2 . The average B factor of 85 Å 2 for the core implies an average amplitude of thermal vibration of u ϭ 1.04 Å (B ϭ 8 2 Ͻu 2 Ͼ). To investigate how well the structure of the high B factor core domain is defined by the density map, a simulated annealing composite omit map was constructed. This was done by leaving out the structure within sequential volumes of the structure throughout the asymmetric unit, and then refining the remainder of the structure by simulated annealing. Omit maps for each ''omitted'' volume were calculated and reassembled into a composite omit map (Fig. 4a) . It revealed continuous density for the backbone and essentially all of the side chains (Fig. 4a) , showing that the high B factor core domain is clearly defined when in the context of this lower B factor C-terminal domain. The source of the higher B factors is suggested by the fact that there is only one very small crystal contact involving the core. The B factors also generally increase with distance from the C-terminal tethering ␣6 helix, implying a rigid body libration of the otherwise well-ordered core domains.
Folds of ␤-sheets within individual C-terminal domains of IN 52-288 , composed of residues 223-228 (␤1), 235-245 (␤2), 248-252 (␤3), 256-260 (␤4), and 265-268 (␤5), are similar to the solution NMR structure for the isolated HIV-1 IN C-terminal domain (18) . The C-terminal domain is a sandwich of two three-stranded antiparallel ␤-sheets. The two three-stranded antiparallel ␤-sheets are formed by a noncontiguous triad of strands ␤1Ϫ␤2Ϫ␤5 (involving the N-terminal end of ␤2) and a contiguous triad of strands ␤2-␤3-␤4 (involving the C-terminal end of ␤2). The longer ␤2 strand transitions between the two sheets and is interrupted between sheets by a cis-proline, P238 (Fig. 4b) . . The vast majority of dimer-dimer contacts in the IN 52-288 crystal structure are mediated by C-terminal domain interactions involving four adjacent dimers that meet around a crystallographic 2-fold axis to form four different types of contacts, interfaces B, BЈ, C, and D (Fig.  5) . Interfaces B and BЈ involve packing of the ␤2-␤3-␤4 sheet against the same ␤2-␤3-␤4 sheet of a 2-fold related molecule in a parallel manner (Fig. 5) . However, a CHAPS molecule wedged between the two sheets, and in contact with L242 and W243, mediates this packing of hydrophobic surfaces. In addition to the rmsd, rms deviation. *R merge ϭ ⌺͉I Ϫ ͗I͘͞⌺͉͗I͉͘; negative intensities included as zero.
C-Terminal Domain Interactions of IN

CHAPS-mediated interactions at this interface, hydrogen bonding and hydrophobic interactions occur between the ␤2-␤3-␤4
sheet and linking helix ␣6 from the 2-fold-related molecule (Fig.  5b) . Because of the kink in the linking ␣6 helix, interface BЈ possesses a greater number of interactions between the ␤2-␤3-␤4 sheet and linking helix ␣6 than does interface B. Interface C involves the antiparallel packing of the noncontiguous ␤1-␤2-␤5 sheets from different dimers against each other (Fig. 5b) . Again, a CHAPS molecule is wedged in between these hydrophobic surfaces, and the only direct contact between sheets is a hydrogen bond between R224N1 and the carbonyl oxygen of W235. Interface D does not lie across a symmetry axis and is formed by edge-to-edge association of the ␤2-␤3 loop 242-246 against the ␤5 strand 265-269 of the symmetry-related molecule (Fig. 5b) .
Discussion
The Y-shaped dimer of HIV-1 IN 52-288 to 2.8-Å resolution is the first reported multidomain structure for HIV-1 IN and can be compared with analogous structures for RSV IN (32) and SIV IN (28) . The introduction of five mutations, C56S, W131D, F139D, F185K, and C280S, did not alter the structure of the catalytic core compared with other structures containing only one of these four mutations, F185K (12) , or mutation F185H (26, 31) . The finding of an identical catalytic core domain structure (44) and RASTER3D (45) . Surface area was calculated by using SURFACE (48) .
alone ) or attached to the C-terminal domain (IN 52-288 ) argues that the dimeric core structure also will be found in full-length IN. The three catalytic residues, D64, D116, and E152, are visible in at least one monomer of IN .
Relationship Between the Catalytic and C-Terminal Domains. The two linking ␣6 helices of the IN 52-288 dimer begin in a 2-fold symmetric manner out to T210. A kink in ␣6 occurs at T210 in one monomer, introducing a 90°rotation of one C-terminal domain and its leading helical stem relative to the other (Fig. 2  b and c) . A previously identified proteolytic cleavage site near T210 suggests that the kink may represent a flexible junction in solution (5) . This flexible elbow within ␣6 may reflect a key functional determinant that permits a dynamic role for each C-terminal domain during the multistep integration process.
In contrast to HIV-1 IN 52-288 , the link between the catalytic and C-terminal domains in the RSV IN structure (32) is comprised of a short, six-residue ␤-strand that immediately deviates at W213 from the 2-fold symmetry of the core. For SIV IN (28), only one of the four C-terminal domains within the asymmetric unit can be resolved. It is packed against helix ␣6 within the core domain, and residues 211-220 of the linking sequence do not form a helix. The different orientations of the catalytic core and C-terminal domains among the RSV, SIV, and HIV-1 IN structures further support the notion of a functional flexibility within the linking sequence.
The NMR structure for residues 220-270 of the HIV-1 C-terminal domain is a dimer involving antiparallel, 2-fold related packing of the contiguous ␤2-␤3-␤4 three-stranded ␤-sheets against each other (16, 17) . Although it differs from all three C-terminal interfaces in the IN 52-288 crystal structure, the NMR dimer interface most closely resembles IN 52-288 interface B that involves the ␤2-␤3-␤4 sheets. However, interface B is mediated by a CHAPS molecule and the sheets in interface B and the NMR structure are packed in opposite orientations. This orientation difference is likely caused by a biologically relevant restriction imposed by having the C-terminal domain linked to the catalytic core domain in IN 52-288 , a restriction not imposed on an isolated C-terminal domain. Although the C-terminal interactions involving adjacent HIV-1 IN 52-288 dimers determine the crystal packing, they and the dimer interface in the isolated C-terminal structure may represent favorable interactions that facilitate the higher-order complex required for properly spaced, concerted integration into the host DNA. Mutagenesis of residues within the C-terminal domains suggests that higher-order oligomerization of HIV-1 IN in solution is facilitated by the C-terminal domains (33, 34) .
The Viral DNA Binding Platform. A contiguous strip of positive charge extending from the catalytic site along the outside face of the IN 52-288 dimer includes residue K159, which can cross-link to the adenine of the invariant 3Ј CA at each viral end (Fig. 3a) (35) . It continues through residues K186, R187, and K188, and out to residues K211, K215, and K219 of the ␣6 helix from the paired monomer in the dimer (Fig. 3a) . This strip of positive potential may provide a platform on which viral att site DNA could be stabilized for 3Ј processing and strand transfer. This putative DNA binding platform involves residues from both monomers within the IN 52-288 dimer, implying that a viral end cleaved in the active site of one monomer is stabilized by residues from the C terminus of the other monomer. This could explain in vitro complementation data in which two inactive IN mutants can be combined to regain IN activity (36, 37) . Docking of an 18-bp viral DNA end to IN 52-288 places the adenine of the conserved viral 3Ј CA in direct contact with K159, places the active site proximal loop involving residues 186-194 in contact with the major groove of the DNA, and places ␣6 helix residues K211, K215, and K219 of the other monomer in contact with the DNA backbone phosphates (Fig. 3b) . In contrast, the structures of two-domain IN from SIV and RSV highlight different putative DNA binding platforms derived from the different spatial arrangements of the C-terminal domain relative to the catalytic core domain. Therefore, the structure of a DNA-bound form of IN will be necessary to distinguish these possibilities.
Residues R263 and K264 in the ␤4-␤5 turn of the HIV-1 IN C-terminal domains can be cross-linked to viral DNA 4 -6 base pairs, 14 -21 Å, from the conserved terminal CA dinucleotide (38 -40) . This distance is much closer than the 62 Å between the catalytic site and R263 in the IN 52-288 structure (Fig. 3b) . The cross-linking data therefore may ref lect interactions between viral DNA held by one dimer and the C-terminal domain from an adjacent dimer. This would require two dimers at each viral end or two IN tetramers in a fully active complex. Interestingly, recent cross-linking data suggested an IN octamer as the active complex for concerted integration of both viral ends (40) . Alternatively, the connecting ␣6 helix of one protomer within a dimer could be extended when binding DNA while the connecting ␣6 helix from the other protomer folds at the f lexible elbow (T210), thereby placing R263 Ϸ20 Å, or one-half turn of duplex DNA, from the conserved CA IN (52-288) , could allow the C-terminal domain to pack against the catalytic core as seen in the SIV IN structure (28) . In any of these models, a f lexible elbow in the linking sequence allows the C-terminal domains to help tether the DNA during the integration process.
Interaction of DNA with the C-Terminal Domain. Two structures of DNA-bound to Src homology 3 (SH3)-like folds are known (41) (42) (43) . The proteins involved, Sso7d and Sac7d, bind in the minor groove of double-stranded DNA in a sequenceindependent manner. Hydrophobic groups on the surface of an SH3-fold ␤-sheet in each protein intercalate into the minor groove of the bound DNA, which widens the groove and sharply kinks the DNA. Although these proteins do not have significant overall sequence homology with the C-terminal domain of HIV-1 IN, alignment of the C-terminal domain crystal structure with those of Sso7d and Sac7d shows that they have similar folds, with rms deviations of 2.2 Å and 1.9 Å, respectively (Fig. 6) . The structural similarity is most pronounced at the ␤-sheet that binds to DNA, which corresponds to the ␤2-␤3-␤4 sheet that figures prominently in the C-terminal interactions observed in the HIV IN 52-288 structure (Fig. 5) . The hydrophobic surface of this IN ␤-sheet, and the corresponding ones in Sso7d and Sac7d, includes a conserved W243 that interfaces with CHAPS in the IN structure and with DNA bases in the Sso7d and Sac7d structures. We speculate that the HIV-1 IN ␤2-␤3-␤4 sheet may bind DNA in a manner analogous to Sso7d and Sac7d.
The diversity and hydrophobic character of the proteinprotein interactions involving the C-terminal domains from HIV-1, RSV (32) , and SIV (28) suggest that they are weak and nonspecific. Because of flexibility in the linker between domains, the C-terminal domains can adopt a wide range of orientations relative to the catalytic core, and none of the protein-protein interactions seen in the crystal structures may actually be present in DNA-bound forms of the protein. The interactions do, however, involve residues that are clustered on the ␤2-␤3-␤4 sheet and on the C-terminal strand ␤5 (Figs. 5 and 6b) , suggesting these are binding epitopes that may contribute to DNA binding and IN oligomerization. HIV-1 IN catalyzes the insertion of the viral cDNA into the human genome and is required for viral replication and pathogenesis (11) . As such, IN is a promising target for the design of anti-HIV drugs. The determination of the twodomain HIV-1 IN structure, IN 52-288 , should prove useful for structure-based efforts to design new IN inhibitors, especially those that may act through perturbation of critical interactions between IN and the viral ends. This can be tested through cocrystallization with DNA and new mutants, experiments that will assist in drug design and will add to our understanding of how IN works.
